All In Biotech

NDA 020122 · Hospira INC

Nipent

Pentostatin · Injection · Nucleoside Metabolic Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Oct 11, 1991

Approved uses

2

Original approval plus efficacy supplements

Registered trials

61

5 Phase 3, 3 recruiting

FAERS reports

1,052

968 serious, 257 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING NIPENT should be administered under the supervision of a physician qualified and experienced in the use of cancer chemotherapeutic agents. The use of higher doses than those specified (see DOSAGE AND ADMINISTRATION ) is not recommended. Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies that used NIPENT at higher doses (20-50 mg/m 2 in divided doses over 5 days) than recommended. In a clinical investigation in patients with refractory chronic lymphocytic leukemia using NIPENT at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity. The use of NIPENT in combination with fludarabine phosphate is not recommended.

What it is approved for

From the label in effect Oct 19, 2026.

INDICATIONS AND USAGE NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.

Therapeutic areas: Cardiovascular and metabolic · Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 29, 1993 Supplement 1 · Efficacy
  • Oct 11, 1991 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • NIPENT · PENTOSTATIN 10MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Pentostatin" as an intervention, any sponsor and status, largest first.

All 61 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia78
  • pyrexia72
  • dyspnoea71
  • diarrhoea62
  • drug ineffective62
  • off label use59
  • pneumonia58
  • sepsis57
  • nausea55
  • anaemia54
  • thrombocytopenia54
  • febrile neutropenia48

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200421
200557
200658
200746
200861
200927
201039
201160
201271
201374
201458
201534
201621
201761
201839
201963
202054
202159
202226
202319
202445
202538
202621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Nipent (Pentostatin) · HCPCS J9268

2024 spending

$424K

Beneficiaries

53

167 claims

Per beneficiary

$8,008

2024 ASP limit $2,421.93 per unit

View as table
YearSpending
2020$626,975
2021$618,018
2022$393,991
2023$781,403
2024$424,420

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 90 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.